Update on Treatment and Prevention of Chronic Antibody Mediated Rejection in Renal Transplant Recipients

Auteurs-es

  • Salman Tahir Shafi Sharif Medical and Dental College, Lahore

DOI :

https://doi.org/10.53778/pjkd40353

Mots-clés :

Rejection, kidney transplant, acute rejection, chronic rejection, antibody mediated rejection, complement,, plasmapheresis, Bortezomib,, Rituximab, Eculizumab, Tocilizumab

Résumé

Chronic antibody mediated rejection (AMR) is a major cause of allograft failure1,2. Chronic AMR clinically presents with proteinuria and gradual decline in renal function. The underlying mechanisms of AMR include both antibody mediated complement-dependent cytotoxicity, complement-independent cellular cytotoxicity and other mechanisms. The purpose of this review is to appraise recent literature on diagnosis, treatment and prevention of chronic AMR.

PJKD

Téléchargements

Publié

2021-01-31

Numéro

Vol. 4 No. 03 (2020): Pakistan Journal of Kidney Diseases

Rubrique

Review Article

Licence

© Salman Tahir Shafi 2021

Licence Creative Commons

Cette œuvre est sous licence Creative Commons Attribution - Pas d'Utilisation Commerciale 4.0 International.

Comment citer

Update on Treatment and Prevention of Chronic Antibody Mediated Rejection in Renal Transplant Recipients. (2021). Pakistan Journal of Kidney Diseases, 4(03). https://doi.org/10.53778/pjkd40353